Aeolus Pharmaceuticals (AOLS)

[Sheep]

Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
MISSION VIEJO, CA--(Marketwired - May 28, 2015) - Aeolus Pharmaceuticals, Inc. (AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the LD Micro Invitational Conference on Tuesday, June 2nd, 2015 at 11:30 AM PDT (2:30 PM EDT) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. Cavalier will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA"). The BARDA contract, worth up to $118.4 million, funds all development costs for the Company's lead compound, AEOL 10150, as a treatment for the pulmonary effects of acute radiation exposure ("Lung-ARS") following a nuclear event.

"We are honored to have Aeolus Pharmaceuticals present at the conference," stated Chris Lahiji, President of LD Micro.

A webcast of the presentation will be available live on the Company's website at www.aolsrx.com. The presentation will also be archived for viewing after the conference


http://finance.yahoo.com/news/aeolus-pharmateucticals-present-ld-micro-113000740.html